Zafgen Issues Statement

MyoKardia Appoints Renowned Cardiovascular Medicine Expert Eric Topol, M.D., to Board of Directors

Foundation Medicine Announces Timing for Third Quarter 2015 Financial Results and Conference Call

Global Blood Therapeutics Announces GBT440 Receives FDA Fast Track Designation for Sickle Cell Disease

Agios to Webcast R&D Day on October 16, 2015

Alcresta to Present at 29th Annual North American Cystic Fibrosis Conference

SAGE to Present Data at Upcoming Scientific Conferences

CytomX Announces Pricing of Initial Public Offering

MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy

SAGE Announces Initiation of Phase 1 and First Dosing of SAGE-217

Jounce Therapeutics Announces Presentation at the Leerink Partners Immuno-Oncology Roundtable

Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies

FierceBiotech names MyoKardia as one of its “Fierce 15†Biotech Companies of 2015

FierceBiotech Names REVOLUTION Medicines as a “Fierce 15†Biotech Company of 2015

Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma

Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma

Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

Zafgen Announces Transition of Board of Directors

bluebird bio Announces Participation in Leerink Partners Immuno-Oncology Roundtable

Global Blood Therapeutics Appoints Philip A. Pizzo, M.D. to Board of Directors

FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome

Seventh Sense Biosystems Announces Expansion of Manufacturing Operations and Facilities in Medford, Massachusetts

Zafgen to Present at the Leerink Rare Disease Roundtable

Agios to Present at Leerink Partners Rare Disease Roundtable

SAGE Therapeutics to Participate in the 4th Annual Leerink Partners Rare Disease Roundtable

SAGE Therapeutics Expands Leadership Team With Key Appointments

Voyager Therapeutics Appoints Neuroscience Expert Steven Hyman, M.D., to Board of Directors

Celgene and Nurix Announce Collaboration Targeting Protein Homeostasis for Next-Generation Therapies in Oncology, Inflammation and Immunology

Foundation Medicine Expands Molecular Information Decision Support Offerings with GeneKitâ„¢, a Genomic Solutions Portal for Pathologists

Foundation Medicine Launches Precision Medicine Exchange Consortiumâ„¢ (PMEC) to Advance the Integration of Molecular Information in Clinical Oncology and Accelerate Adoption of Precision Care

Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial Officer

bluebird bio Announces Participation at Morgan Stanley Global Healthcare Conference

Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis

Zafgen to Present at Morgan Stanley Global Healthcare Conference

Foundation Medicine to Present at Morgan Stanley Global Healthcare Conference

Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes

SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor

Global Blood Therapeutics Announces Participation at Three September Conferences

Blueprint Medicines to Present at the 22nd Annual NewsMakers in the Biotech Industry Conference

Blueprint Medicines to Present Preclinical Data on BLU-554 and on Novel Drug Target at International Liver Cancer Association 9th Annual Conference

Eleven Biotherapeutics Announces Promotions of Gary Sternberg, MD, MBA to Chief Business Officer and John McCabe, CPA to Senior Vice President, Finance

Eleven Biotherapeutics to Present at NewsMakers in the Biotech Industry Conference

Foundation Medicine to Webcast Investor & Analyst Day

CytomX Files Registration Statement for Proposed Initial Public Offering

Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer

Global Blood Therapeutics Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Seventh Sense Biosystems Receives Four Patent Allowances for TAP Blood Collection System in the U.S. and Europe

Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results

Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing